Expert Interview
A Third Look: Discussing the latest results from the Phase 3 SEQUOIA-HCM trial of aficamten in patients with symptomatic obstructive hypertrophic cardiomyopathy.
Ticker(s): CYTKInstitution: Bay Area Cardiology
- Clinical Cardiologist who has been in practice for 16 years with a Fellowship focused in Clinical Cardiac Electrophysiology Residency Program from Duke University.
- Skilled in Complex ablations, Defibrillator, Medical Devices, Catheters, Cardiac Electrophysiology, and Cardiology.
- Treats approximately 100+ heart failure patients in both inpatient and outpatient locations monthly and has used Verquvo in 25-30 patients.
- Manages 150-160 patients with elevated Lp(a) and is familiar with the olpasiran data
Do you want answers to these questions?
Slingshot Insights Explained
Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.
Reason
*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.
